The FDA has approved Journavx, a new type of pain medication developed by Vertex Pharmaceuticals, designed to address the risks of addiction and overdose commonly associated with opioids. Journavx is intended for short-term pain relief following surgery or injuries and offers an alternative to both opioids and over-the-counter pain relievers like ibuprofen and acetaminophen. While studies show modest effectiveness compared to opioids and acetaminophen, experts highlight its unique mechanism of action and potential for future development.
MATTHEW PERRONEU.S. officials have approved a new type of pain drug designed to eliminate the risks of addiction and overdose associated with opioids.Federal officials on Thursday approved a new type of pain pill designed to eliminate the risks of addiction and overdose associated with opioid medications like Vicodin and OxyContin.
Studies in more than 870 patients with acute pain due to foot and abdominal surgeries showed Vertex's drug provided more relief than a dummy pill but didn't outperform a common opioid-acetaminophen combination pill. Vertex began researching the drug in the 2000s, when overdoses were rocketing upward, principally driven by mass prescribing of opioid painkillers for common ailments like arthritis and back pain. Prescriptions have fallen sharply in the last decade and the current wave of the opioid epidemic is mainly due to illicit fentanyl, not pharmaceutical medicines.
"In trying to develop medicines that don't have the addictive risks of opioid medicines, a key factor is working to block pain signaling before it gets to the brain," Vertex's Dr. David Altshuler, told The Associated Press last year."The new medication has side effect profiles that are inherently, not only different, but don't involve the risk of substance abuse and other key side effects associated with opioids," said Dr.
PAIN MANAGEMENT NON-OPIOIDS FDA APPROVAL ADDICTION RISK VERTEX PHARMACEUTICALS
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
FDA Approves Vertex's Non-Opioid Painkiller Journavx, Offering Hope for Millions Suffering from PainVertex Pharmaceuticals' non-opioid painkiller, Journavx, receives FDA approval, marking a significant milestone in the fight against the opioid epidemic. The drug offers a safe and effective alternative for pain relief without the risk of addiction.
Read more »
FDA Approves Vertex Pharmaceuticals' Non-Opioid Painkiller JournavxThe Food and Drug Administration (FDA) has approved Vertex Pharmaceuticals' non-opioid painkiller, Journavx, marking a significant step forward in safer pain management. This milestone comes after years of efforts to develop alternatives to addictive opioids. Journavx works by blocking pain signals at their source, unlike opioids which directly impact the brain.
Read more »
FDA Approves New Nonopioid Pain Killer JournavxThe FDA has approved a new nonopioid painkiller, Journavx, for moderate to severe acute pain in adults. This could potentially reduce opioid prescriptions after surgery or provide an alternative for those who can't tolerate other pain medications.
Read more »
New Drug Journavx Offers Hope for Reduced Opioid Use After SurgeryJournavx, a nonaddictive drug developed by Vertex Pharmaceuticals, has shown promising results in clinical trials for reducing post-surgical pain. Experts believe it could significantly reduce the reliance on opioid painkillers.
Read more »
Journavx: A Promising New Drug for Acute Pain ReliefVertex Pharmaceuticals' Journavx, a non-addictive pain reliever, has shown significant promise in clinical trials, potentially reducing reliance on opioids for acute pain management. The FDA approved drug targets a specific sodium channel, blocking pain signals from reaching the brain, offering a safer alternative for patients.
Read more »
New Drug Journavx Shows Promise in Reducing Post-Surgery PainVertex Pharmaceuticals' Journavx, a nonaddictive drug for moderate to severe acute pain, has been approved by the FDA. Experts believe it could reduce opioid prescriptions after surgery or for patients who can't tolerate other pain medications. While initial trials show promising results, some experts call for further research.
Read more »